6IGC の概要
| エントリーDOI | 10.2210/pdb6igc/pdb |
| 分子名称 | Major capsid protein L1 (1 entity in total) |
| 機能のキーワード | capsid protein, structural protein |
| 由来する生物種 | Human papillomavirus type 58 |
| タンパク質・核酸の鎖数 | 40 |
| 化学式量合計 | 2365772.04 |
| 構造登録者 | |
| 主引用文献 | Li, Z.,Song, S.,He, M.,Wang, D.,Shi, J.,Liu, X.,Li, Y.,Chi, X.,Wei, S.,Yang, Y.,Wang, Z.,Li, J.,Qian, H.,Yu, H.,Zheng, Q.,Yan, X.,Zhao, Q.,Zhang, J.,Gu, Y.,Li, S.,Xia, N. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Nat Commun, 9:5360-5360, 2018 Cited by PubMed Abstract: Sequence variability in surface-antigenic sites of pathogenic proteins is an important obstacle in vaccine development. Over 200 distinct genomic sequences have been identified for human papillomavirus (HPV), of which more than 18 are associated with cervical cancer. Here, based on the high structural similarity of L1 surface loops within a group of phylogenetically close HPV types, we design a triple-type chimera of HPV33/58/52 using loop swapping. The chimeric VLPs elicit neutralization titers comparable with a mix of the three wild-type VLPs both in mice and non-human primates. This engineered region of the chimeric protein recapitulates the conformational contours of the antigenic surfaces of the parental-type proteins, offering a basis for this high immunity. Our stratagem is equally successful in developing other triplet-type chimeras (HPV16/35/31, HPV56/66/53, HPV39/68/70, HPV18/45/59), paving the way for the development of an improved HPV prophylactic vaccine against all carcinogenic HPV strains. This technique may also be extrapolated to other microbes. PubMed: 30560935DOI: 10.1038/s41467-018-07199-6 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (3.5 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
をダウンロード
